Pharmaceuticals

VariZIG Market 2026 strengthening with post-exposure prophylaxis demand

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The VariZIG Market Across 2026–2030?

Historical growth was fueled by the accessibility of plasma fractionation technologies, a heightened understanding of varicella-related complications, the broadening of hospital-based prophylaxis guidelines, regulatory clearances for hyperimmune globulin products, and a well-developed immunization infrastructure.

The growth anticipated in the forecast period is primarily driven by an increasing demand for the protection of immunocompromised patients, a heightened emphasis on maternal and neonatal care, the expansion of plasma collection networks, significant advancements in biologic safety screening, and a rising investment in preventive immunotherapies. Concurrently, major trends expected during this period involve the wider adoption of passive immunization therapies, an escalating focus on the protection of high-risk patients, the broadening of plasma-derived biologic product offerings, an intensified emphasis on post-exposure prophylaxis, and the implementation of more effective cold-chain management practices.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20448&type=smp

What Drivers Are Shaping The Future Growth Of The VariZIG Market?

The varizig market is projected to expand due to the rising incidence of varicella-zoster virus infections. The varicella-zoster virus (VZV) is a highly transmissible pathogen causing chickenpox as its initial manifestation, with the potential to reactivate later in life as shingles (herpes zoster). The increase in VZV infections, leading to conditions like chickenpox and shingles, can be attributed to factors such as reduced vaccination rates, an aging population, and immune suppression from medical treatments. varizig assists varicella-zoster virus patients by conferring passive immunity, thereby reducing the intensity and duration of chickenpox symptoms, preventing severe complications in high-risk individuals such as immunocompromised patients, and offering protection against adverse outcomes in neonates and pregnant women exposed to the virus. For instance, according to the Florida Department of Health, a US government agency, in November 2024, the number of varicella cases in 2023 climbed to 653, an increase from 428 cases recorded in 2022. Therefore, the growing occurrence of varicella-zoster virus infections is a significant driver for the varizig market.

What Segmentation Levels Are Considered In The VariZIG Market?

The varizig market covered in this report is segmented –

1) By Patient Condition: Immunocompromised Patients, Pregnant Women

2) By Distribution Channel: Hospitals, Pharmacies, Healthcare Providers

3) By End User: Adult, Geriatric, Pediatric

What Trends Are Projected To Affect The VariZIG Market?

Leading companies operating in the VariZIG market are concentrating on technological progress, specifically in the areas of manufacturing scale-up and advanced distribution logistics. These improvements include optimizing contract manufacturing, establishing regional supply-chain agreements, and enhancing cold-chain and stability to guarantee the timely delivery of plasma-derived immunoglobulins to high-need populations. The concept of manufacturing scale-up and distribution logistics involves a series of process and infrastructure innovations designed to increase production capacity, implement robust cold-chain and inventory management, secure regional supply agreements, and coordinate procurement contracts. These efforts aim to transform limited specialist biologic products from niche availability into dependable, regionally accessible therapies. As an illustration, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical firm specializing in plasma-derived treatments, announced a $25 million three-year contract to supply KAMRAB and VariZIG throughout Latin America from 2025 until 2027. This agreement ensures regional supply and reduces the potential for shortages among vulnerable patients, thereby allowing hospitals and public health systems to plan preventative measures and treatments with enhanced certainty. Furthermore, it broadens commercial reach within a market that was previously disjointed, by fostering predictable demand and establishing robust distribution channels across numerous nations, which in turn facilitates quicker patient access. Lastly, the contract strengthens public health readiness concerning varicella exposure for high-risk populations by guaranteeing a dependable supply route for a crucial passive-immunity product.

Which Leading Firms Are Contributing To The Growth Of The VariZIG Market?

Major companies operating in the varizig market are Emergent BioSolutions Inc.

Read the full varizig market report here:

https://www.thebusinessresearchcompany.com/report/varizig-global-market-report

Which Geographic Regions Are Influencing Demand In The VariZIG Market?

North America was the largest region in the varizig market in 2025. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored VariZIG Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20448&type=smp

Browse Through More Reports Similar to the Global VariZIG Market 2026, By The Business Research Company

Esg Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/esg-finance-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795